Understand the source comparison
Selank Amidate Clinical Trials 2026: Trial Type Comparison
Phase II RCT (Moscow) HAM-A score reduction ≥30% from baseline 180 participants 12 weeks PET scan GABA receptor density at baseline and week 8 Largest cohort with neuroimaging. Gold standard for mechanism validation Investigator-Initiated (Kyiv) Cortisol AUC r
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Phase II RCT (Moscow)
- HAM-A score reduction ≥30% from baseline
- 180 participants
- 12 weeks
- PET scan GABA receptor density at baseline and week 8
- Largest cohort with neuroimaging. Gold standard for mechanism validation
- Investigator-Initiated (Kyiv)
- Cortisol AUC reduction and CANTAB cognitive battery
- 60 participants
- 8 weeks
- None (biomarker-only)
- Lower cost, faster completion, but lacks receptor imaging data
- Observational Cohort (Tbilisi)
- Subjective anxiety self-report and adverse event tracking
- 30 participants
- 4 weeks
- None
- Limited endpoint rigor. Serves as safety monitoring rather than efficacy validation
- Preclinical Follow-Up (Rodent)
- BDNF mRNA expression and hippocampal neurogenesis markers
- N/A (animal model)
- 6 weeks
- Immunohistochemistry brain tissue analysis
- Mechanistic depth but no direct human translation. Supports hypothesis generation